CUTERA, INC. announced that Taylor Harris has been appointed Chief Executive Officer, effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as members of Cutera?s Board of Directors.

Mr. Harris joined Cutera?s Board in June 2023. He is a proven executive and brings over 20 years of operational expertise as well as healthcare and life science industry experience to the Company. He most recently served as Senior Vice President and Chief Financial Officer of MyoKardia, a clinical-stage biopharmaceutical company, until the company?s sale to Bristol Myers Squibb in 2020.

Previously, Mr. Harris served as Senior Vice President and Chief Financial Officer of ZELTIQ Aesthetics, where he was responsible for overseeing global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company?s commercial operations, including customer service, product support, and inside sales. Mr. Harris also served as Chief Financial Officer at Thoratec Corporation, and prior to that he worked at JP Morgan Chase & Co. for over a decade with a focus on the medical device industry.

Mr. Harris served as the Chief Financial Officer for MyoKardia, from 2018 until that company's acquisition by Bristol Myers Squibb in 2020. Prior to that, Mr. Harris served as Senior Vice President and Chief Financial Officer of ZELTIQ Aesthetics, until that company?s acquisition by Allergan plc. He also served as Vice President and Chief Financial Officer at Thoratec Corporation, which was eventually acquired by St.

Jude Medical, Inc. and worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm?s Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a B.A. from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain scholar.